Cancer Vaccines
Challenges and Opportunities in Translation
Herausgeber: Bot, Adrian; Obrocea, Mihail
Cancer Vaccines
Challenges and Opportunities in Translation
Herausgeber: Bot, Adrian; Obrocea, Mihail
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Recent advances in immunology and biology have opened new horizons in cancer therapy. This work is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.
Andere Kunden interessierten sich auch für
- R H GoldfarbTumor Immunology and Cancer Therapy329,99 €
- H C StevensonAdoptive Cellular Immunotherapy of Cancer319,99 €
- Neville WillmottMicrospheres and Regional Cancer Therapy494,99 €
- Biosensors and Cancer263,99 €
- 50 Landmark Papers every Intensivist Should Know176,99 €
- Stem Cells297,99 €
- Gene Regulation and Therapeutics for Cancer253,99 €
-
-
-
Recent advances in immunology and biology have opened new horizons in cancer therapy. This work is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.
Produktdetails
- Produktdetails
- Verlag: Taylor and Francis
- Seitenzahl: 238
- Erscheinungstermin: 1. April 2008
- Englisch
- Abmessung: 234mm x 152mm x 20mm
- Gewicht: 503g
- ISBN-13: 9781420054675
- ISBN-10: 1420054678
- Artikelnr.: 23373391
- Verlag: Taylor and Francis
- Seitenzahl: 238
- Erscheinungstermin: 1. April 2008
- Englisch
- Abmessung: 234mm x 152mm x 20mm
- Gewicht: 503g
- ISBN-13: 9781420054675
- ISBN-10: 1420054678
- Artikelnr.: 23373391
ADRIAN BOT is Senior Director of Scientific Management and Acting Head of Translational Medicine at MannKind Corporation, in Valencia, California. He obtained his M.D. at the University of Medicine and Pharmacy in Timisoara, Romania and his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York. He previously held appointments at the Scripps Research Institute and Alliance Pharmaceutical Corporation in San Diego. Dr. Bot authored more than one hundred publications and patents in oncology, vaccines, drug delivery technologies and immunotherapy. He is the Editor-in-Chief of the International Reviews of Immunology and has been on advisory boards of several organizations. MIHAIL OBROCEA is Vice President, Clinical Development, MannKind Corporation, Paramus, New Jersey. Dr. Obrocea received his M.D. from the Faculty of Medicine and Pharmacy, Bucharest, Romania. He is a medical oncologist with over 10 years of academic and industry experience in oncology clinical trials, including biologic agents, small molecules and cytotoxic agents. Dr. Obrocea has published in oncology peer-reviewed literature, and has various patents in the field of biotechnology.
SECTION I - Basic Aspects: Tumor Antigens and Preclinical Modelling. 1.
Factoring in antigen processing in designing anti-tumor T-cell vaccines. 2.
Outlining the gap between preclinical models and clinical situation.
SECTION II - Cell Based, Anti-infectious and Personalized Vaccines. 3.
THERAPEUTIC AND PROPHYLACTIC CANCER VACCINES - EMERGING PERSPECTIVES FROM
ALLOGENEIC AND INFECTIOUS DISEASE VACCINES. 4. Personalized Cancer
Vaccines. 5. Dendritic cell vaccines for gliomas. SECTION III.
INTRACEREBRAL HEMORRHAGE (ICH). 6. Peptide based active immunotherapy in
cancer. 7. Multimodality Immunization Approaches to Improve on DNA Vaccines
for Cancer. 8. Bidirectional Bedside Lab Bench Processes and Flexible Trial
Design as a Means to Expedite the Development of Novel Immunotherapeutics.
9. Diagnostic approaches for selecting patient-customized therapies,
obviating tumor variability to maximize therapeutic effect.
Factoring in antigen processing in designing anti-tumor T-cell vaccines. 2.
Outlining the gap between preclinical models and clinical situation.
SECTION II - Cell Based, Anti-infectious and Personalized Vaccines. 3.
THERAPEUTIC AND PROPHYLACTIC CANCER VACCINES - EMERGING PERSPECTIVES FROM
ALLOGENEIC AND INFECTIOUS DISEASE VACCINES. 4. Personalized Cancer
Vaccines. 5. Dendritic cell vaccines for gliomas. SECTION III.
INTRACEREBRAL HEMORRHAGE (ICH). 6. Peptide based active immunotherapy in
cancer. 7. Multimodality Immunization Approaches to Improve on DNA Vaccines
for Cancer. 8. Bidirectional Bedside Lab Bench Processes and Flexible Trial
Design as a Means to Expedite the Development of Novel Immunotherapeutics.
9. Diagnostic approaches for selecting patient-customized therapies,
obviating tumor variability to maximize therapeutic effect.
SECTION I - Basic Aspects: Tumor Antigens and Preclinical Modelling. 1.
Factoring in antigen processing in designing anti-tumor T-cell vaccines. 2.
Outlining the gap between preclinical models and clinical situation.
SECTION II - Cell Based, Anti-infectious and Personalized Vaccines. 3.
THERAPEUTIC AND PROPHYLACTIC CANCER VACCINES - EMERGING PERSPECTIVES FROM
ALLOGENEIC AND INFECTIOUS DISEASE VACCINES. 4. Personalized Cancer
Vaccines. 5. Dendritic cell vaccines for gliomas. SECTION III.
INTRACEREBRAL HEMORRHAGE (ICH). 6. Peptide based active immunotherapy in
cancer. 7. Multimodality Immunization Approaches to Improve on DNA Vaccines
for Cancer. 8. Bidirectional Bedside Lab Bench Processes and Flexible Trial
Design as a Means to Expedite the Development of Novel Immunotherapeutics.
9. Diagnostic approaches for selecting patient-customized therapies,
obviating tumor variability to maximize therapeutic effect.
Factoring in antigen processing in designing anti-tumor T-cell vaccines. 2.
Outlining the gap between preclinical models and clinical situation.
SECTION II - Cell Based, Anti-infectious and Personalized Vaccines. 3.
THERAPEUTIC AND PROPHYLACTIC CANCER VACCINES - EMERGING PERSPECTIVES FROM
ALLOGENEIC AND INFECTIOUS DISEASE VACCINES. 4. Personalized Cancer
Vaccines. 5. Dendritic cell vaccines for gliomas. SECTION III.
INTRACEREBRAL HEMORRHAGE (ICH). 6. Peptide based active immunotherapy in
cancer. 7. Multimodality Immunization Approaches to Improve on DNA Vaccines
for Cancer. 8. Bidirectional Bedside Lab Bench Processes and Flexible Trial
Design as a Means to Expedite the Development of Novel Immunotherapeutics.
9. Diagnostic approaches for selecting patient-customized therapies,
obviating tumor variability to maximize therapeutic effect.